The leaders in pharmaceutical innovation have been truly love-hate recently. Innovent and WuXi AppTec keep getting positive news, and foreign investors are buying enthusiastically, but the price action shows no real improvement... BeiGene, on the other hand, gave some face with a slight rise, and many are probably just passively waiting for the options expiry. CanSino and RemeGen have wild swings—some get caught up in the frenzy and end up spinning in circles, while the bullish breakout I’ve been waiting for still hasn’t come. Honestly, whether you buy or not now comes with a built-in exhaustion buff. Is it worth it long-term? Still agonizing over it.






